latanoprost


Also found in: Medical, Wikipedia.
Translations

latanoprost

n latanoprost m
References in periodicals archive ?
Aerie's second product for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa and the widely-prescribed PGA (prostaglandin analog) latanoprost, has been approved by the FDA and is now available in the United States.
The NCX 470 Clinical Study went head-to-head on a daily dose of the treatment versus Latanoprost, which is perceived as the number one treatment for glaucoma and ocular hypertension.
i EYE DROP LATANOPROST 0.005% + TIMOLOL 0 5% BOTTLE As Per H
Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa and the widely-prescribed PGA(prostaglandin analog) latanoprost, has been approved by the FDA and was launched in the United States in the second quarter of 2019.
In these studies, Rocklatan achieved its primary 90-day efficacy endpoint as well as positive 12-month safety and efficacy results, demonstrating statistically superior IOP reduction over latanoprost and netarsudil at every measured time point.
Hilson's most recent outing, Latanoprost Variations, continues this trend in striking fashion.
With its Phase 2 multi-centre, double-masked, 28-day, parallel group, dose ranging Phase 2 study, the company aims to evaluate the efficacy and safety of NCX 470 in comparison to latanoprost 0.005% in adult patients with elevated IOP due to open-angle glaucoma or ocular hypertension.
In July 2017, the company announced top-line results of its Phase 2 fixed-dose combination trial of trabodenoson and latanoprost for the treatment of glaucoma.
The currently prescribed PGAs in our region are bimatoprost 0.01% (with BAK 0.02%), latanoprost 0.005% (with BAK 0.02%), travoprost 0.004% (with 0.001% polyquad), and tafluprost 0.0015% (preservative-free).
Later in 2014, Kucukevcilioglu and coworkers (2) described deepening of the upper eyelid sulcus in other PA, such as Latanoprost and Travoprost.
Tafluprost is a PGA with pharmacological properties similar to those of latanoprost and it is characterized by the absence of preservatives (FOGAGNOLO et al., 2015; KWAK et al., 2017).
The second group received standard medical therapy with latanoprost (Xalatan[R]) eye drops,